Clinical trials: High-Risk Cancer
Newly Diagnosed High Risk Neuroblastoma
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
- Trial name
- NCT02771743
- Testing
- Cisplatin, Doxorubicin, Etoposide
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Samsung Medical Center
JAK2 Mutation
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm.
- Trial name
- NCT07249840
- Testing
- Ropeginterferon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer
Protection of Rectum From High Radiation Doses
The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.
- Trial name
- NCT01601691
- Testing
- DuraSeal
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- University of Oulu
Glioblastoma, Malignant Glioma
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
This trial assesses the quality of life in patients with high grade glioma and their caregivers using a questionnaire called the Beacon Patient Related Outcomes Quality of Life (PROQOL).
- Conditions
- Glioblastoma, Malignant Glioma, WHO Grade III Glioma
- Trial name
- NCT04630379
- Testing
- Palliative Therapy, Quality-of-Life Assessment, Supportive Care
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Oral Squamous Cell Carcinoma
"Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON)
Oral diseases are currently diagnosed by means of clinical examination and supported by surgical biopsy procedures. In particular, daily oral medicine practice is lacking the use of a routine diagnostic support to the…
- Trial name
- HOUSTON (NCT06336941)
- Testing
- Ultrasound
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University of Pisa
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Total neoadjuvant treatment (TNT) including radiotherapy and induction or consolidation systemic chemotherapy has become the standard treatment for patients with stage II and III rectal adenocarcinoma.
- Trial name
- PREDIR-NEOREC (NCT06762405)
- Testing
- radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Early-stage Breast Cancer
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival.
- Trial name
- NCT05332561
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib
- Where
- 9 sites in Germany
- Volunteers
- 240 people
- Sponsor
- German Cancer Research Center
Anastomotic Leak, Anastomotic Leak Large Intestine
Low Tie Versus High Tie of the Inferior Mesenteric Vein During Colorectal Cancer Surgery: A Randomized Clinical Trial
This study aim to determine if a different surgical technique could result in a lower anastomotic leak rate. The two techniques are equally used around the world and well described by the international literature but this is the…
- Conditions
- Anastomotic Leak, Anastomotic Leak Large Intestine, Anastomotic Leak Rectum, Colon Cancer
- Trial name
- LOTHVEIN (NCT05411783)
- Testing
- Low tie of IMV
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- San Carlo di Nancy Hospital
Recurrent High-grade Glioma
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.
- Trial name
- NCT04822805
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people
- Sponsor
- First People's Hospital of Hangzhou
High Grade Glioma, Brain Cancer
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Immune checkpoint blockade therapies targeting the immunomodulatory effect of cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death-1/ Programmed death-ligand 1 (PD-1/PD-L1) have recently demonstrated survival benefit…
- Trial name
- REVOLUMAB (NCT03925246)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High Grade Serous Ovarian Cancer
miRNAs in High Grade Serous Ovarian Cancer
High grade serous ovarian cancer represents the gynecological malignancy with the highest incidence of mortality. Decision-making tools are currently limited to the use of standard imaging modalities and analysis of serum…
- Trial name
- MIROC (NCT05146505)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bladder Cancer
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
A significant number of patients with high risk superficial bladder cancer has progression to invasive disease. No consensus exists regarding the optimal treatment to decrease the recurrence and progression rate.
- Trial name
- NCT00696579
- Testing
- BCG, gemcitabine
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- University Of Perugia
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Neoplasms
A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer
This study is designed to determine the maximum tolerated dose of vitamin C when given with a standard chemotherapy for people who have metastatic pancreatic cancer.
- Trial name
- NCT01049880
- Testing
- Gemcitabine with escalating ascorbic acid
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joseph J. Cullen
Brain and Central Nervous System Tumors, Lymphoma
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity
- Trial name
- NCT00734773
- Testing
- Rituximab, Cytarabine, Methotrexate
- Sponsor
- Northwestern University
Secondary Malignant Neoplasm of Bone
Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU
This study is to confirm the safety and technical of MRI guided High Intensity Focused Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases.
- Trial name
- NCT01117246
- Testing
- High Intensity Focused Ultrasound
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Philips Healthcare
Heavy Smoking
Bronchoscopy Screening for High-risk Population of Lung Cancer With Severe Smoking With Negative LDCT Screen
Based on the previous work of LDCT screening, in order to improve the screening rate of central lung cancer for LDCT negative and severe smokers, the investigators plan to conduct China's first large-scale fluorescent…
- Trial name
- NCT04413669
- Testing
- white light bronchoscopy & autofluorescence bronchoscopy
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Jiayuan Sun
Non-small Cell Lung Cancer Stage I
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
Brief Summary The goal of this clinical trial is to evaluate the effect of postoperative adjuvant chemotherapy (ACT) in patients with stage I non-squamous non-small cell lung cancer (NSCLC) after curative resection.
- Trial name
- NCT07250360
- Testing
- Adjuvant chemotheapy
- Volunteers
- 2,072 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer Patients, Rectal Cancer Stage II
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan…
- Conditions
- Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07176182
- Testing
- mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group, mFOLFOX regimen neoadjuvant therapy group
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.